Brokerages Expect Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post $0.14 EPS

Equities research analysts expect Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) to announce $0.14 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is $0.15 and the lowest is $0.13. Catalyst Pharmaceuticals posted earnings of $0.11 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 27.3%. The company is expected to announce its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full year earnings of $0.69 per share for the current fiscal year, with EPS estimates ranging from $0.65 to $0.73. For the next financial year, analysts expect that the company will post earnings of $0.85 per share, with EPS estimates ranging from $0.80 to $0.95. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Rating) last announced its earnings results on Wednesday, March 16th. The biopharmaceutical company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.03). Catalyst Pharmaceuticals had a net margin of 28.03% and a return on equity of 23.50%. During the same period in the previous year, the firm earned $0.11 EPS.

A number of brokerages recently commented on CPRX. Piper Sandler raised their target price on Catalyst Pharmaceuticals from $8.00 to $8.75 in a report on Thursday, March 17th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 24th. HC Wainwright lifted their price objective on Catalyst Pharmaceuticals from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, February 7th. Finally, Truist Financial reiterated a “buy” rating and issued a $12.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, March 18th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.00.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Brandywine Global Investment Management LLC raised its position in shares of Catalyst Pharmaceuticals by 0.6% during the 3rd quarter. Brandywine Global Investment Management LLC now owns 351,642 shares of the biopharmaceutical company’s stock worth $1,864,000 after acquiring an additional 2,014 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Catalyst Pharmaceuticals by 1.0% during the 3rd quarter. Macquarie Group Ltd. now owns 213,006 shares of the biopharmaceutical company’s stock worth $1,129,000 after acquiring an additional 2,200 shares in the last quarter. Point72 Hong Kong Ltd raised its position in shares of Catalyst Pharmaceuticals by 84.3% during the 4th quarter. Point72 Hong Kong Ltd now owns 5,932 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 2,713 shares in the last quarter. Teacher Retirement System of Texas raised its position in shares of Catalyst Pharmaceuticals by 17.4% during the 4th quarter. Teacher Retirement System of Texas now owns 18,642 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 2,757 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Catalyst Pharmaceuticals by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 135,492 shares of the biopharmaceutical company’s stock worth $917,000 after acquiring an additional 2,866 shares in the last quarter. 62.13% of the stock is currently owned by institutional investors and hedge funds.

Shares of Catalyst Pharmaceuticals stock opened at $7.62 on Wednesday. The business has a 50-day moving average of $7.98 and a 200 day moving average of $7.08. Catalyst Pharmaceuticals has a 12 month low of $4.43 and a 12 month high of $8.65. The stock has a market capitalization of $782.96 million, a price-to-earnings ratio of 20.59 and a beta of 1.30.

About Catalyst Pharmaceuticals (Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Read More

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.